668 related articles for article (PubMed ID: 23837756)
21. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
22. Advances in treatment for relapses and refractory multiple myeloma.
Richards T; Weber D
Med Oncol; 2010 Jun; 27 Suppl 1():S25-42. PubMed ID: 20213220
[TBL] [Abstract][Full Text] [Related]
23. NICE guidance on pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib.
Burke MJ; George E; Adler AI
Lancet Oncol; 2015 May; 16(5):492-3. PubMed ID: 25818587
[No Abstract] [Full Text] [Related]
24. Pomalidomide therapy for myeloma.
Schey S; Ramasamy K
Expert Opin Investig Drugs; 2011 May; 20(5):691-700. PubMed ID: 21413906
[TBL] [Abstract][Full Text] [Related]
25. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
Richardson PG; Siegel D; Baz R; Kelley SL; Munshi NC; Laubach J; Sullivan D; Alsina M; Schlossman R; Ghobrial IM; Doss D; Loughney N; McBride L; Bilotti E; Anand P; Nardelli L; Wear S; Larkins G; Chen M; Zaki MH; Jacques C; Anderson KC
Blood; 2013 Mar; 121(11):1961-7. PubMed ID: 23243282
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone for heavily pretreated relapsed or refractory multiple myeloma.
Jimenez-Zepeda VH; Reece DE; Trudel S; Chen C; Tiedemann R; Kukreti V
Leuk Lymphoma; 2013 Mar; 54(3):555-60. PubMed ID: 22881043
[TBL] [Abstract][Full Text] [Related]
27. Current treatment landscape for relapsed and/or refractory multiple myeloma.
Dimopoulos MA; Richardson PG; Moreau P; Anderson KC
Nat Rev Clin Oncol; 2015 Jan; 12(1):42-54. PubMed ID: 25421279
[TBL] [Abstract][Full Text] [Related]
28. Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy.
Sonneveld P; Hajek R; Nagler A; Spencer A; Bladé J; Robak T; Zhuang SH; Harousseau JL; Orlowski RZ;
Cancer; 2008 Apr; 112(7):1529-37. PubMed ID: 18300257
[TBL] [Abstract][Full Text] [Related]
29. Pomalidomide: new immunomodulatory agent with potent antiproliferative effects.
Richardson PG; Mark TM; Lacy MQ
Crit Rev Oncol Hematol; 2013 Oct; 88 Suppl 1():S36-44. PubMed ID: 23786844
[TBL] [Abstract][Full Text] [Related]
30. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
31. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
32. The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience.
Charlinski G; Grzasko N; Jurczyszyn A; Janczarski M; Szeremet A; Waszczuk-Gajda A; Bernatowicz P; Swiderska A; Guzicka-Kazimierczak R; Lech-Maranda E; Szczepaniak A; Wichary R; Dmoszynska A
Eur J Haematol; 2018 Sep; 101(3):354-361. PubMed ID: 29882602
[TBL] [Abstract][Full Text] [Related]
33. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
34. The emerging role of novel therapies for the treatment of relapsed myeloma.
Richardson PG; Hideshima T; Mitsiades C; Anderson KC
J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
[TBL] [Abstract][Full Text] [Related]
35. Novel therapies in myeloma.
Hayden PJ; Mitsiades CS; Anderson KC; Richardson PG
Curr Opin Hematol; 2007 Nov; 14(6):609-15. PubMed ID: 17898564
[TBL] [Abstract][Full Text] [Related]
36. Overview of drug therapy for multiple myeloma.
Saunders G
J Oncol Pharm Pract; 2005 Sep; 11(3):83-100. PubMed ID: 16390597
[TBL] [Abstract][Full Text] [Related]
37. Impact of pomalidomide therapy in multiple myeloma: a recent survey.
Kumar A; Porwal M; Verma A; Mishra AK
J Chemother; 2014 Dec; 26(6):321-7. PubMed ID: 25004945
[TBL] [Abstract][Full Text] [Related]
38. Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide.
Oka S; Ono K; Nohgawa M
J Clin Pharm Ther; 2018 Dec; 43(6):914-917. PubMed ID: 29974481
[TBL] [Abstract][Full Text] [Related]
39. The role of novel drugs in multiple myeloma.
Dimopoulos MA; Kastritis E
Ann Oncol; 2008 Sep; 19 Suppl 7():vii121-7. PubMed ID: 18790953
[No Abstract] [Full Text] [Related]
40. Management of older patients with multiple myeloma.
Gay F; Palumbo A
Blood Rev; 2011 Mar; 25(2):65-73. PubMed ID: 21295387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]